CanSino Inhaled COVID-19 Vaccine Approved in China as Booster
publication date: Sep 9, 2022
Tianjin CanSino Biologics reported that an aerosolized version of its COVID-19 vaccine has been approved for China use as a COVID booster vaccine. CanSino pointed to preliminary study results showing the inhaled vaccine provided immunity after a single dose, but the company did not release detailed efficacy results. The company’s COVID-19 vaccine, which is delivered by an adenovirus Type 5 vector, is 65% effective at preventing all symptomatic COVID-19 disease and 90% effective at preventing severe disease. CanSino partnered the COVID vaccine with the Beijing Institute of Biotechnology, Academy of Military Medical Sciences. More details....
Stock Symbols: (SHA: 688185; HK: 06185)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.